Trends in thyroid cancer demographics and surgical therapy in the United States
Ian C. Mitchell(The University of Texas Southwestern Medical Center), Fiemu E. Nwariaku(The University of Texas Southwestern Medical Center), Alice Y. Chang(Jacksonville College), Ildiko Lingvay(Southwestern Medical Center), Shelby Holt(Southwestern Medical Center), William H. Snyder(The University of Texas Southwestern Medical Center), Edward H. Livingston(The University of Texas Southwestern Medical Center)
Cited by 78
Related Papers
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
|The Lancet Diabetes & Endocrinology|2018|758
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
|Diabetes Care|2017|574
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
|The Lancet|2021|555
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|514